Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Sep 21;35(3):279-296.
doi: 10.1515/jpem-2021-0369. Print 2022 Mar 28.

Congenital hyperinsulinism: recent updates on molecular mechanisms, diagnosis and management

Affiliations
Review

Congenital hyperinsulinism: recent updates on molecular mechanisms, diagnosis and management

Dinesh Giri et al. J Pediatr Endocrinol Metab. .

Abstract

Congenital hyperinsulinism (CHI) is a rare disease characterized by an unregulated insulin release, leading to hypoglycaemia. It is the most frequent cause of persistent and severe hypoglycaemia in the neonatal period and early childhood. Mutations in 16 different key genes (ABCC8, KCNJ11, GLUD1, GCK, HADH, SLC16A1, UCP2, HNF4A, HNF1A, HK1, KCNQ1, CACNA1D, FOXA2, EIF2S3, PGM1 and PMM2) that are involved in regulating the insulin secretion from pancreatic β-cells have been described to be responsible for the underlying molecular mechanisms of CHI. CHI can also be associated with specific syndromes and can be secondary to intrauterine growth restriction (IUGR), maternal diabetes, birth asphyxia, etc. It is important to diagnose and promptly initiate appropriate management as untreated hypoglycaemia can be associated with significant neurodisability. CHI can be histopathologically classified into diffuse, focal and atypical forms. Advances in molecular genetics, imaging techniques (18F-fluoro-l-dihydroxyphenylalanine positron emission tomography/computed tomography scanning), novel medical therapies and surgical advances (laparoscopic pancreatectomy) have changed the management and improved the outcome of patients with CHI. This review article provides an overview of the background, clinical presentation, diagnosis, molecular genetics and therapy for children with different forms of CHI.

Keywords: hyperinsulinism; hypoglycaemia; insulin dysregulation.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Aynsley-Green, A, Hussain, K, Hall, J, Saudubray, JM, Nihoul-Fekete, C, De Lonlay-Debeney, P, et al.. Practical management of hyperinsulinism in infancy. Arch Dis Child Fetal Neonatal Ed 2000;82:F98–107. https://doi.org/10.1136/fn.82.2.f98.
    1. Hussain, K, Blankenstein, O, De Lonlay, P, Christesen, HT. Hyperinsulinaemic hypoglycaemia: biochemical basis and the importance of maintaining normoglycaemia during management. Arch Dis Child 2007;92:568–70. https://doi.org/10.1136/adc.2006.115543.
    1. Senniappan, S, Shanti, B, James, C, Hussain, K. Hyperinsulinaemic hypoglycaemia: genetic mechanisms, diagnosis and management. J Inherit Metab Dis 2012;35:589–601. https://doi.org/10.1007/s10545-011-9441-2.
    1. Yau, D, Laver, TW, Dastamani, A, Senniappan, S, Houghton, JAL, Shaikh, G, et al.. Using referral rates for genetic testing to determine the incidence of a rare disease: the minimal incidence of congenital hyperinsulinism in the UK is 1 in 28,389. PLoS One 2020;15:e0228417. https://doi.org/10.1371/journal.pone.0228417.
    1. Demirbilek, H, Hussain, K. Congenital hyperinsulinism: diagnosis and treatment update. J Clin Res Pediatr Endocrinol 2017;9:69–87. https://doi.org/10.4274/jcrpe.2017.S007.

LinkOut - more resources